Vous avez été déconnecté
Les modifications faites ici s’appliquent uniquement aux informations de votre compte Sanofi Connect. Si vous souhaitez modifier vos informations Swiss RX, veuillez vous rendre sur leur site directement
Schwartz GG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682-689.
Schwartz GG et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107.
Szarek M, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;73(4):387-396.
Jukema JW, et al. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;74(9):1167-1176.
Steg PG, et al. Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation. 2019;140(2):103-112.
We’ve researched far and wide to collect the results for ODYSSEY OUTCOMES, a cardiovascular outcomes trial with alirocumab (a PCSK9 inhibitor).